Solution enables cost-effective retrofitting of legacy systems with industry-leading PNT resilienceCHANDLER, Ariz., May 28, 2025 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) today announced the launch of its second-generation RSR Transcoder, created to maintain operational capability in GPS/GNSS-denied, degraded or disrupted space operational environments (D3SOE). The second generation RSR Transcoder delivers assured Position, Navigation and Timing (PNT) in a wide range of outputs to upgr ...

ADTRAN Holdings, Inc. (ADTN) has unveiled its latest Positioning, Navigation and Timing (PNT) solution, the OSA aPNT+ platform, at Jammertest 2024 in Norway. The platform integrates various PNT sources, including Iridium Satellite Time and Location (STL) services to effectively reduce risks and set new standards for securing applications in the public and private sectors. Adtran's Oscilloquartz aPNT+ solution utilizes a multi-layered strategy that includes advanced Global Navigation Satellite Systems (GNSS) ...

Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (IRS Employer Identification No.) incorporation or organization) 4850 West 78th Street Indianapolis, IN 46268 (Address of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or other j ...

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 85-0 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 85-080049 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or other j ...

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Washington, D.C. 20549 FORM 10-K Commission File Number 001-39311 POINT BIOPHARMA GLOBAL INC. (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 4850 West 78th Street, Indianapolis, IN 46268 (647) 812-2417 (Address, including zip ...